Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Change in Receivables (2019 - 2025)

Cyclerion Therapeutics has reported Change in Receivables over the past 7 years, most recently at -$425000.0 for Q3 2025.

  • Quarterly results put Change in Receivables at -$425000.0 for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was $100000.0 (changed N/A YoY), and the annual figure for FY2024 was $556000.0, up 679.17%.
  • Change in Receivables for Q3 2025 was -$425000.0 at Cyclerion Therapeutics, down from -$56000.0 in the prior quarter.
  • Over the last five years, Change in Receivables for CYCN hit a ceiling of $556000.0 in Q4 2024 and a floor of -$425000.0 in Q3 2025.
  • Median Change in Receivables over the past 5 years was -$56000.0 (2025), compared with a mean of -$9769.2.
  • Peak annual rise in Change in Receivables hit 200.0% in 2022, while the deepest fall reached 200.0% in 2022.
  • Cyclerion Therapeutics' Change in Receivables stood at -$285000.0 in 2021, then surged by 54.04% to -$131000.0 in 2022, then grew by 26.72% to -$96000.0 in 2023, then surged by 679.17% to $556000.0 in 2024, then plummeted by 176.44% to -$425000.0 in 2025.
  • The last three reported values for Change in Receivables were -$425000.0 (Q3 2025), -$56000.0 (Q2 2025), and $25000.0 (Q1 2025) per Business Quant data.